136 related articles for article (PubMed ID: 34590053)
1. Severe Immune Checkpoint Inhibitor Hepatitis in
Begum P; Goldin RD; Possamai LA; Popat S
JTO Clin Res Rep; 2021 Sep; 2(9):100213. PubMed ID: 34590053
[TBL] [Abstract][Full Text] [Related]
2. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS
Chour A; Denis J; Mascaux C; Zysman M; Bigay-Game L; Swalduz A; Gounant V; Cortot A; Darrason M; Fallet V; Auclin E; Basse C; Tissot C; Decroisette C; Bombaron P; Giroux-Leprieur E; Odier L; Brosseau S; Creusot Q; Gueçamburu M; Meersseman C; Rochand A; Costantini A; Gaillard CM; Wasielewski E; Girard N; Cadranel J; Lafitte C; Lebossé F; Duruisseaux M
J Thorac Oncol; 2023 Oct; 18(10):1408-1415. PubMed ID: 37217096
[TBL] [Abstract][Full Text] [Related]
4. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
Iska S; Alley EW
Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
[TBL] [Abstract][Full Text] [Related]
5. Mixed response to the first-line treatment of KRAS G12C inhibitor, sotorasib, in non-small cell lung cancer: A brief report.
Yang J; Huang J; Yuan G; Lin XC; Chen HJ; Yang JJ
Clin Case Rep; 2024 Jun; 12(6):e8866. PubMed ID: 38799516
[TBL] [Abstract][Full Text] [Related]
6. CodeBreak 200: Sotorasib Has Not Broken the KRAS
Zhang SS; Lee A; Nagasaka M
Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
[TBL] [Abstract][Full Text] [Related]
7. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
Brazel D; Kim J; Ou SI
Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
[TBL] [Abstract][Full Text] [Related]
8. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
10. Activity of sotorasib against brain metastases from NSCLC harboring
Inno A; Marchetti F; Valerio M; Giaj Levra N; Alongi F; Foti G; Gori S
Drug Target Insights; 2023; 17():90-91. PubMed ID: 37408855
[TBL] [Abstract][Full Text] [Related]
11. Remarkable Intracranial Response to Sotorasib in a Patient With
Yeh J; Marks JA; Alzeer AH; Sloan EA; Varghese R; Paudel N; Reuss JE; Bergquist PJ; Liu SV; Kim C
JTO Clin Res Rep; 2022 Dec; 3(12):100428. PubMed ID: 36471683
[TBL] [Abstract][Full Text] [Related]
12. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
[TBL] [Abstract][Full Text] [Related]
13. Sotorasib as first-line therapy in patients with advanced non-small cell lung cancer with KRAS gene mutations combined with brain metastases: a case report.
Jia X; Liu M; Cheng Z
AME Case Rep; 2024; 8():48. PubMed ID: 38711902
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Cancer Control With Adagrasib in Patients With Metastatic,
Stratton N; Thompson J
JTO Clin Res Rep; 2024 Apr; 5(4):100661. PubMed ID: 38550295
[TBL] [Abstract][Full Text] [Related]
15. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
16. Sotorasib Shows Intracranial Activity in Patients with
Koster KL; Appenzeller C; Lauber A; Früh M; Schmid S
Case Rep Oncol; 2022; 15(2):720-725. PubMed ID: 36157699
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on Sotorasib (AMG 510) for
Zhang SS; Nagasaka M
Lung Cancer (Auckl); 2021; 12():115-122. PubMed ID: 34675734
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with
Zhou KI; Lin C; Tseng CL; Ramnath N; Dowell JE; Kelley MJ
JTO Clin Res Rep; 2024 May; 5(5):100670. PubMed ID: 38746048
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS
Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC
J Thorac Oncol; 2024 Apr; ():. PubMed ID: 38615940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
